Affiliations of authors: NSABP Operations Center, Pittsburgh, PA (RES, NM); NSABP Biostatistical Center, Pittsburgh, PA (LC, HSW, MB)
Correspondence to: Roy Smith, MD, National Surgical Adjuvant Breast and Bowel Project (NSABP), East Commons Professional Bldg., Four Allegheny Center5th Floor, Pittsburgh, PA 15212-5234 (e-mail: melissa.wolfe{at}nsabp.org)
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
![]() |
INTRODUCTION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Eligibility criteria, treatment plans, and follow-up procedures have been described previously (1). The purpose of this report is to provide an update of the results from the complete 10-year data. Follow-up was discontinued at 10 years because nearly all recurrences were observed in the first 5 years of the study, and almost no deaths after 10 years would have been related to cancer recurrence.
![]() |
PATIENTS AND METHODS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
After stratification by Dukes stage, sex, and age (<65 years or 65 years), a total of 1166 patients with colon cancer at institutions in the United States and Canada had curative surgery and then were randomly assigned between November 15, 1977, and February 28, 1983, to no further treatment (394 patients), postoperative MOF chemotherapy (379 patients), or postoperative immunotherapy (393 patients). There was no blinding of treatment, and no patients received placebo. Three hundred seventy-five (95.2%) of those assigned to the surgery-alone group, 349 (92.1%) of those assigned to the chemotherapy group, and 372 (94.7%) of those assigned to the immunotherapy group were considered eligible for follow-up; 95.9% of the patients contributed complete survival information at 10 years, meaning that they had been monitored for 10 years or died before 10 years of follow-up. Of these 1166 patients, 70 (6.0%) patients were ineligible. The reasons for ineligibility for 46 of these patients were previously reported in detail (1). Since that last report, 24 patients have been found to be ineligible: 14 because of questionable informed consent, six because they had Dukes stage D disease, three because they had Dukes stage A disease, and another patient because he was found to have concurrent rectal cancer. At the time of this analysis, the primary reasons for ineligibility included concurrent cancer in the rectum (19 patients), Dukes stage other than B or C (26 patients), and questionable informed consent (14 patients).
The randomization generated comparable treatment groups. Age, sex, lymph node status (positive versus negative), and location of primary tumor were well balanced in the three randomization arms, although there was a previously noted imbalance in that 9% of the patients who received chemotherapy, 6% of those who received immunotherapy, and 30% of those who underwent surgery alone had eight or more positive lymph nodes (1). Notably, there was a prerandomization phase to this trial, and 80 patients who were randomly assigned to treatment during this phase did not accept their assigned treatment arm (13 in the surgery-alone group, 30 in the chemotherapy group, and 37 in the immunotherapy group). An additional 25 patients assigned to chemotherapy and 27 patients assigned to immunotherapy never started therapy. All patients provided written informed consent to participate in the study, for which local internal review boards reviewed and approved the protocol and consent forms.
Statistical Methods
All analyses used in graphs and tables are based on the 1096 (116670 ineligible patients) eligible patients as randomly assigned, as are the majority of analyses discussed in the remaining text. We present a few additional analyses in which the patients who did not receive therapy were omitted to verify that the results remained essentially unchanged. Whenever patients who did not receive therapy were omitted, we explicitly state this fact.
Disease-free survival and overall survival were estimated with KaplanMeier curves (2). Relapse-free survival curves were also calculated with the KaplanMeier method, in which case patients who had not relapsed (i.e., had no recurrence of disease) were censored at the time of a second primary tumor or death. For the primary analyses, a Cox proportional hazards model was used to compare overall survival, disease-free survival, and relapse-free survival among the treatment groups, stratifying by the number of positive lymph nodes (0, 14, 57, or 8 positive lymph nodes, but the exact number was unknown). We should note that the treatment effect did not maintain a proportional hazard across time, as during the first 5 years the majority of the events are cancer related, which is not the case in the second 5 years. (A test in which a treatment-by-time interaction action was added to the model was statistically significant for all the curves that were presented.) Partly for this reason, we present both 5-year and 10-year results. We performed secondary analyses in which the treatments were included in a Cox proportional hazards model with number of lymph nodes, age, sex, and location. Risk ratios were obtained from this model (3,4). The score test from a Cox model was used to test for differences between treatment groups (5). All statistical tests were two-sided. Follow-up time was measured from the date of surgery, and all follow-up was censored at 10 years. The analyses were conducted with the SAS program package (6). To test for interactions between treatment and prognostic factors, we fit one model with the treatment, the prognostic factors, and the interaction terms. We then fit a model with only treatment and prognostic factors. Finally, we computed the difference between 2-log likelihood for the model with the main effects and interaction terms and 2-log likelihood for the model with only the main effects to determine whether addition of the interaction terms resulted in a statistically significant difference (P<.05). Had these results been statistically significant, we would then have performed further analyses to identify which interactions caused this effect.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In the previous report on the first 5 years after randomization (1), it was estimated that treatment with surgery alone, compared with surgery plus adjuvant chemotherapy, was associated with an increased risk of treatment failure (relative risk [RR] = 1.29, 95% confidence interval [CI] = 1.03 to 1.61; P = .03) and with an increased risk of dying (RR = 1.31, 95% CI = 1.02 to 1.68; P = .05). At that time, however, not all patients had been monitored for 5 years. As of this report, the 5-year disease-free survival and overall survival were statistically significantly different between the two arms (for disease-free survival, RR = 1.29 [95% CI = 1.03 to 1.61]; P =.03; and for overall survival, RR = 1.29 [95% CI = 1.01 to 1.66]; P =.04). However, during the subsequent 5 years (years 610), these differences became less pronounced, and with complete 10-year data, the differences for 10-year disease-free survival and overall survival between the two arms became statistically nonsignificant (for disease-free survival, hazard ratio [HR] = 1.14 [95% CI = 0.94 to 1.39]; P = .17; and for overall survival, HR = 1.12 [95% CI = 0.91 to 1.38]; P = .27) (Fig. 1, A and B). Restricting these analyses to the patients who received therapy had essentially no impact on the results (for disease-free survival, P = .13; for overall survival, P = .29). However, there was an apparent benefit in favor of chemotherapy that was detected as early as 1 year from the date of randomization and that persisted for up to 8 years of follow-up (Fig. 1, A and B). For 10-year relapse-free survival (Fig. 1, C), the benefit occurred during the first 5 years, which is consistent with overall survival differences persisting for 8 years.
|
The acute toxic effects associated with the chemotherapy regimen used in the C-01 trial have been previously reported (1). Chronic or late chemotherapyassociated toxic effects appeared to be isolated primarily in the hematologic system. Three patients were diagnosed with acute myelocytic leukemia, and five developed myelodysplastic syndromes. All of these patients have since died. Three of four patients who developed prolonged bone marrow hypoplasia have died, and two of three patients who developed non-Hodgkin lymphoma have died. In addition, there was a chemotherapy-related nephrotoxic event in one patient. Of patients who received immunotherapy, three developed non-Hodgkin lymphoma and one died. A surgery-alone patient who presented with chronic lymphocytic leukemia later died.
Adjuvant Immunotherapy Compared With Surgery Alone
In contrast to the chemotherapy and surgery-alone groups, the disease-free survival curves of those who received immunotherapy and those who received surgery alone were virtually superimposable until year 4 after randomization (Fig. 2). Immunotherapy did not appear to prevent tumor relapse (for surgery alone versus immunotherapy, RR = 0.99, 95% CI = 0.78 to 1.25; P = .93) but, nevertheless, had a beneficial effect on 10-year overall survival (for surgery alone versus immunotherapy, RR = 1.27, 95% CI = 1.03 to 1.56; P = .02). These results for 10-year overall survival were essentially unaffected when the analyses were restricted to patients who received their assigned treatment (for relapse-free survival, RR = 0.94 [95% CI = 0.74 to 1.21]; P = .64; and for overall survival, RR = 1.24 [95% CI = 1.00 to 1.54]; P = .05). This improvement in overall survival appeared to be due to a smaller number of deaths from comorbidities rather than to a decrease in deaths after recurrent colon cancer. In the immunotherapy arm, there were fewer cardiac-related deaths, deaths after second primary cancers other than colon cancer, and deaths from other nonmalignant conditions (Table 1). The reduction in deaths after second primary cancer on this arm could not be attributed to any specific site of second primary cancer.
|
|
|
An analysis of baseline variables indicates that age, sex, tumor location, and number of lymph nodes involved with tumors were of prognostic importance for survival. However, sex, age, and tumor location were not statistically significant prognostic factors for tumor recurrence (Table 2).
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The results of this study also demonstrated a continued advantage at 10 years for patients treated with nonspecific BCG immunotherapy, although this difference remained statistically significant only for overall survival. It is of interest that, unlike what we saw in the comparison of the chemotherapy-treated group with the surgery-alone group, the curves for disease-free survival and overall survival between the immunotherapy and surgery-alone groups did not begin to separate until after 4 years of follow-up. This observation raises the possibility that immunotherapy alters the natural history of the comorbidities commonly associated with this patient population whose members, at the time of this analysis, were predominantly older than 65 years. In the 5-year report (1), calculations that omitted deaths without disease recurrence demonstrated that immunotherapy had no direct benefit on disease-free survival, and this result is also supported by our 10-year re-analysis of relapse-free survival and disease-free survival.
In conclusion, the findings from this analysis after 10 years of follow-up continue to indicate that the disease-free survival and overall survival benefit from the use of MOF chemotherapy in this patient population is of limited duration. The overall survival advantage associated with immunotherapy when compared with surgery alone appears to be unrelated to a beneficial alteration in the natural course of the primary malignancy. This observed difference was associated with a reduction in deaths associated with comorbid conditions in this elderly population. It is possible that this observation reflects a real differential effect of immunotherapy on these comorbidities, although we cannot rule out the possibility that this is a chance finding because it was an unanticipated effect, and there were two primary end points and two treatment comparisons.
![]() |
NOTES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
This investigation was supported by Public Health Service grants NCI-U10-CA-69651, NCI-U10-CA-12027, NCI-U10-CA-37377, and NCI-U10-CA-69974 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1 Wolmark N, Fisher B, Rockette H, Redmond C, Wickerham DL, Fisher E, et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:306.
2 Cutler SJ, Ederer F. Maximum utilization of the life table method on analyzing survival. J Chronic Dis 1958;8:699712.[Medline]
3 Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:16370.[Medline]
4 Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc (A) 1972;135:185206.[ISI]
5 Hankey BF, Myers MH. Evaluating differences in survival between two groups of patients. J Chronic Dis 1971;24:52331.[ISI][Medline]
6 SAS Institute Inc. SAS/STAT user's guide, version 6. Vol. 1. 4th ed. Cary (NC): SAS Institute Inc.; 1989.
7 Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:3528.[Abstract]
8 O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997;15:24650.[Abstract]
9 Wolmark N, Rockette H, Fisher B, Wickerham DL, Redmond C, Fisher ER, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol 1993;11:187987[Abstract]
Manuscript received August 22, 2003; revised May 25, 2004; accepted June 9, 2004.
This article has been cited by other articles in HighWire Press-hosted journals:
Correspondence about this Article
Editorial about this Article
Related Memo to the Media
![]() |
||||
|
Oxford University Press Privacy Policy and Legal Statement |